A5070650932- Renal Transplantation Outcomes and Treatments
- Pharmacological Effects and Toxicity Studies
- Renal Diseases and Glomerulopathies
- Hepatitis C virus research
- Hepatitis B Virus Studies
- Neurological Complications and Syndromes
- Hepatitis Viruses Studies and Epidemiology
- Acute Kidney Injury Research
- Complement system in diseases
- Adolescent and Pediatric Healthcare
- Polyomavirus and related diseases
- Herpesvirus Infections and Treatments
- Child Nutrition and Feeding Issues
- Dialysis and Renal Disease Management
- Pharmaceutical studies and practices
- Transplantation: Methods and Outcomes
- Bone and Joint Diseases
- Central Venous Catheters and Hemodialysis
- Antibiotics Pharmacokinetics and Efficacy
- Hemoglobinopathies and Related Disorders
- Antibiotic Resistance in Bacteria
- HIV/AIDS drug development and treatment
- Epilepsy research and treatment
- Muscle and Compartmental Disorders
- Cytomegalovirus and herpesvirus research
Horizon Therapeutics (United States)
2024
Cincinnati Children's Hospital Medical Center
2015-2023
Children's Medical Center
2019
Highlights•Eculizumab is a promising therapeutic option in HSCT recipients with high-risk TMA.•Eculizumab clearance depends on TMA disease activity.•Plasma sC5b-9 concentration can be used to determine eculizumab dosing regimen.•CH50 monitoring aids decision discontinue therapy when controlled.•PK/PD-guided improves survival TMA.AbstractThrombotic microangiopathy (TMA) after hematopoietic stem cell transplantation (HSCT) associated terminal complement activation, as measured by elevated...
Abstract Background BK viremia after kidney transplantation (KT) poses significant risk for virus‐associated nephropathy and impacts graft survival. Conventional treatment involves reduction of immunosuppression, which in turn may increase rejection. To address this dilemma, use anti‐viral therapy with immunosuppressive properties such as leflunomide is an attractive option. Methods We performed a multi‐center, retrospective chart review to report tolerability effectiveness the eradication...
Background: Studies in adult patients suggest cefepime can cause neurotoxicity, including disorientation, seizures, and coma, particularly when present at high concentrations. Patients with underlying kidney dysfunction or central nervous system anomalies are risk. There is a relative paucity of pediatric literature on the neurotoxic effects cefepime. Case Report: Herein reported case 2-year-old patient chronic disease receiving for Serratia marcescens bacteremia who experienced agitation,...
Tacrolimus, the most common immunosuppressant for organ transplant, has a narrow therapeutic range and is metabolized by CYP3A4/5. Trough concentration monitoring dosing adjustments are used to reach range. CYP3A5 intermediate normal metabolizers (*1 allele carriers; IM/NM) demonstrate faster tacrolimus metabolism than poor (PM). We analyzed electronic health records of 93 patients aged <21 years first 8 weeks after kidney transplant between January 2010 December 2021. The target trough was...
Abstract Since hepatitis B virus ( HBV ) vaccine implementation, infection has significantly decreased. However, adult renal transplant recipients show a higher rate of seroreversion compared to the general population, leading risk. Data are limited in pediatric recipients. Retrospective data were collected determine seroprotection and durability vaccination patients from 2004 2014. One hundred subjects categorized based on pre‐ post‐transplant surface antibody HB sAb). Pretransplant, 85...
An optimal cytomegalovirus (CMV) prevention strategy following solid organ transplantation (SOT) remains uncertain. This study reports on the rates of CMV events a change in local guideline involving increased surveillance, earlier transition to oral valganciclovir, and decreased CMV-immunoglobulin use.A retrospective cohort utilizing historical controls evaluated invasive disease pre- post-intervention among pediatric heart, liver, kidney recipients. Outcomes were recorded for 4 years...
Considerable interpatient and interoccasion variability has been reported in tacrolimus pharmacokinetics (PK) the pediatric renal transplant population. This study investigated PK a 2-year-old post-renal patient known CYP3A5 expresser who developed posterior reversible encephalopathy syndrome (PRES) had significantly elevated blood concentrations during treatment. A model-informed assessment was performed to assist with precision dosing. Tacrolimus clearance evaluated both before after...
To date, the evidence for proteasome-inhibitor (PI) based antibody mediated rejection (AMR) therapy has been with first-generation PI bortezomib. Results have demonstrated encouraging efficacy early AMR lesser late AMR. Unfortunately, bortezomib is associated dose-limiting adverse effects in some patients. We report use of second generation proteosome inhibitor carfilzomib treatment two pediatric patients a kidney transplant.The clinical data on who experienced dose limiting toxicities from...
Background: Nephrotoxic medication exposure is a common cause of acute kidney injury (AKI) in hospitalized children and associated with chronic disease (CKD). The pharmacist-reliant NINJA program reduced nephrotoxic AKI. Objectives: We assess potential healthcare cost savings from CKD by preventing AKI the for pediatric population through age 21. Methods: simulated cohort 1000 non-critically ill children. From published literature, 310 develop AKI, 267 survive to 6 months, 10-70% CKD,...
Caldwell, John; Lazear, Danielle; Miyagawa, Bradley; Mizuno, Tomoyuki; Quinn, Charles T.; Stone, Hillarey; Hooper, David K.; Varnell, D. Author Information